Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice-Chair for Cellular Therapies.
Roswell Park Comprehensive Cancer Center is the first center to treat patients in a newly opened advanced-stage clinical trial utilizing the brain cancer vaccine SurVaxM, offering a new treatment option for patients who are dealing with ...
Meet Lindsay Lipinski, MD, FAANS. Dr. Lipinski brings exertise in peripheral nerve tumors and entrapment neuropathies to the Roswell Park Neuro-Oncology Team.
Clinical Trial of Roswell Park’s SurVaxM Glioblastoma Vaccine Reveals Promising Results.
Roswell Park Comprehensive Cancer Center Professor of Neurosurgery Michael Ciesielski, PhD, presented the most recent findings from the completed phase 2A study of the immunotherapy SurVaxM at a poster session in June at the American Society ...
First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM
The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM.